findmyKOL

Haifaa Abdulhaq, MD

Basic profile

California State University, Fresno

ORCIDNPI
RegionFresno, CA · WestSpecialtyHematology / OncologyFocusOncology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Haifaa Abdulhaq is an Oncology physician affiliated with California State University, Fresno. OpenAlex indexes 82 publications with 518 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
82publications

Distinct works indexed by OpenAlex, matched via ORCID.

518citations

Total citations across indexed works.

10h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
38companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

38 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    26.4%
    Kinase inhibitor8.6%
    Jakafi20%Sprycel18%Iclusig10%Calquence9%Imbruvica8%Ibrance7%Tafinlar6%Mekinist6%Tagrisso5%Everolimus5%Brukinsa5%
    Part D<11 patients
    Thalidomide Analog6.5%
    Lenalidomide44%Revlimid35%Pomalyst21%
    Part D17 patients

    + 9 more classes in this area

  • Metabolism & gastrointestinal

    17.5%
    Serotonin-3 Receptor Antagonist4.8%
    Ondansetron Hcl47%Ondansetron Odt44%Sancuso9%
    Part D<11 patients
    Corticosteroid4.6%
    Prednisone100%
    Part D60 patients

    + 3 more classes in this area

  • Dermatology

    13.5%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.5%
    Acyclovir100%
    Part D84 patients
    Corticosteroid1%
    Triamcinolone Acetonide100%
    Part D16 patients
Where care is delivered (Part B)11.3% facility · 88.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”